02/01/2019 Daptomycin and linezolid for treating vancomycin-resistant enterococci bloodstream infections
The Ministry of Health’s Drug Advisory Committee has recommended:
- Linezolid 600 mg tablet and 2 mg/ml solution for infusion for treating patients with culture-positive vancomycin-resistant enterococci (VRE) bloodstream infections.
Subsidy status
RLinezolid 600 mg tablet and 2 mg/ml solution for infusion are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.
RTreatment with linezolid should be initiated and monitored by an infectious disease specialist.
NRMAF assistance does not apply to any other non-bloodstream culture-positive VRE infections treated with linezolid.
NRMAF assistance does not apply to daptomycin 500 mg vial.